Global Blood Therapeutics Stock News

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics is enjoying strong fundamental improvement amid the biotech bear market.

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

The past year was a transformational time for Global Blood Therapeutics. The company was able to report growth for its flagship product, Oxbryta, in the face of COVID-19 headwinds.

ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund is pleased to announce the addition of five new members to its national volunteer Board of Trustees, all of whom have worked throughout their careers to advance health equity and advocate for improvements to health care and quality of life for all those affected by kidney disease. The new members who joined the board effective March 4 are: Kenneth R. Bridges, MD, Principal Medical Director and Vice President of Medical Affairs at Global Blood Therapeutics. Dr. Bridges has worked for many years to address issues of health disparities; he also serves as the founder and director of the International Sickle Cell Anemia Foundation. Oliver T. Brooks, MD, Chief Medical Officer at Watts Healthcare Corporation and Medical Director for L.A. Care Health Plan. Dr. Brooks, immediate past president of the National Medical Association, is a nationally recognized leader on health care in communities of color and has participated in AKF''s congressional briefing and Unknown Causes of Kidney Disease Summit .

Global Blood Therapeutics (NASDAQ: GBT ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 These 4 analysts have an average price target of $56.5 versus the current price of Global Blood Therapeutics at $29.15, implying upside. Below is a summary of how these 4 analysts rated Global Blood Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive … Full story available on Benzinga.com

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

GBT earnings call for the period ending December 31, 2021.

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2021 Results - Earnings Call Transcript

Global Blood Therapeutics press release (GBT): Q4 GAAP EPS of -$1.36 misses by $0.23.Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M.Cash, cash equivalents, and marketable…

Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?